FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4378650289> ?p ?o ?g. }

• W4378650289 endingPage "2966" @default.
• W4378650289 startingPage "2966" @default.
• W4378650289 abstract "(1) Background: The main objectives of our study are (i) to determine the prevalence of NTRK (neurotrophic tyrosine kinase) fusions in a routine diagnostic setting in NSCLC (non-small cell lung cancer) and (ii) to investigate the feasibility of screening approaches including immunohistochemistry (IHC) as a first-line test accompanied by fluorescence in situ hybridization (FISH) and RNA-(ribonucleic acid-)based next-generation sequencing (RNA-NGS). (2) Methods: A total of 1068 unselected consecutive patients with NSCLC were screened in two scenarios, either with initial IHC followed by RNA-NGS (n = 973) or direct FISH testing (n = 95). (3) Results: One hundred and thirty-three patients (14.8%) were IHC positive; consecutive RNA-NGS testing revealed two patients (0.2%) with NTRK fusions (NTRK1-EPS15 (epidermal growth factor receptor pathway substrate 15) and NTRK1-SQSTM1 (sequestosome 1)). Positive RNA-NGS was confirmed by FISH, and NTRK-positive patients benefited from targeted treatment. All patients with direct FISH testing were negative. RNA-NGS- or FISH-positive results were mutually exclusive with alterations in EGFR (epidermal growth factor receptor), ALK (anaplastic lymphoma kinase), ROS1 (ROS proto-oncogene 1), BRAF (proto-oncogene B-Raf), RET (rearranged during transfection) or KRAS (kirsten rat sarcoma viral oncogene). Excluding patients with one of these alterations raised the prevalence of NTRK-fusion positivity among panTrk-(tropomyosin receptor kinase-) IHC positive samples to 30.5%. (4) Conclusions: NTRK fusion-positive lung cancers are exceedingly rare and account for less than 1% of patients in unselected all-comer populations. Both RNA-NGS and FISH are suitable to determine clinically relevant NTRK fusions in a real-world setting. We suggest including panTrk-IHC in a diagnostic workflow followed by RNA-NGS. Excluding patients with concurrent molecular alterations to EGFR/ALK/ROS1/BRAF/RET or KRAS might narrow the target population." @default.
• W4378650289 created "2023-05-30" @default.
• W4378650289 creator A5009622543 @default.
• W4378650289 creator A5028935333 @default.
• W4378650289 creator A5038314386 @default.
• W4378650289 creator A5040984119 @default.
• W4378650289 creator A5044155836 @default.
• W4378650289 creator A5046304194 @default.
• W4378650289 creator A5046639150 @default.
• W4378650289 creator A5053452787 @default.
• W4378650289 creator A5069663433 @default.
• W4378650289 creator A5089214384 @default.
• W4378650289 creator A5090147778 @default.
• W4378650289 creator A5092043390 @default.
• W4378650289 date "2023-05-29" @default.
• W4378650289 modified "2023-10-18" @default.
• W4378650289 title "NTRK Gene Fusions in Non-Small-Cell Lung Cancer: Real-World Screening Data of 1068 Unselected Patients" @default.
• W4378650289 cites W1494352958 @default.
• W4378650289 cites W1667088041 @default.
• W4378650289 cites W1975784282 @default.
• W4378650289 cites W1976059757 @default.
• W4378650289 cites W1979188008 @default.
• W4378650289 cites W2000161913 @default.
• W4378650289 cites W2008264953 @default.
• W4378650289 cites W2030514091 @default.
• W4378650289 cites W2049674541 @default.
• W4378650289 cites W2053343049 @default.
• W4378650289 cites W2062220374 @default.
• W4378650289 cites W2062291041 @default.
• W4378650289 cites W2109269285 @default.
• W4378650289 cites W2110540279 @default.
• W4378650289 cites W2127368054 @default.
• W4378650289 cites W2154727263 @default.
• W4378650289 cites W2251438188 @default.
• W4378650289 cites W2258072747 @default.
• W4378650289 cites W2259419843 @default.
• W4378650289 cites W2307442092 @default.
• W4378650289 cites W2335155752 @default.
• W4378650289 cites W2339257776 @default.
• W4378650289 cites W2345898309 @default.
• W4378650289 cites W2586526035 @default.
• W4378650289 cites W2586704604 @default.
• W4378650289 cites W2590981502 @default.
• W4378650289 cites W2738437255 @default.
• W4378650289 cites W2790254562 @default.
• W4378650289 cites W2883016549 @default.
• W4378650289 cites W2885210084 @default.
• W4378650289 cites W2888845108 @default.
• W4378650289 cites W2896424462 @default.
• W4378650289 cites W2898539999 @default.
• W4378650289 cites W2899710937 @default.
• W4378650289 cites W2900674461 @default.
• W4378650289 cites W2907628865 @default.
• W4378650289 cites W2936879991 @default.
• W4378650289 cites W2953495640 @default.
• W4378650289 cites W2965810912 @default.
• W4378650289 cites W2976640752 @default.
• W4378650289 cites W2982100308 @default.
• W4378650289 cites W2996493142 @default.
• W4378650289 cites W2996574710 @default.
• W4378650289 cites W2997752668 @default.
• W4378650289 cites W3003818830 @default.
• W4378650289 cites W3025060587 @default.
• W4378650289 cites W3028426009 @default.
• W4378650289 cites W3037250269 @default.
• W4378650289 cites W3110682386 @default.
• W4378650289 cites W3154701325 @default.
• W4378650289 cites W3184058448 @default.
• W4378650289 cites W4281740556 @default.
• W4378650289 cites W4282601439 @default.
• W4378650289 cites W4308477179 @default.
• W4378650289 cites W4327703895 @default.
• W4378650289 doi "https://doi.org/10.3390/cancers15112966" @default.
• W4378650289 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37296928" @default.
• W4378650289 hasPublicationYear "2023" @default.
• W4378650289 type Work @default.
• W4378650289 citedByCount "2" @default.
• W4378650289 countsByYear W43786502892023 @default.
• W4378650289 crossrefType "journal-article" @default.
• W4378650289 hasAuthorship W4378650289A5009622543 @default.
• W4378650289 hasAuthorship W4378650289A5028935333 @default.
• W4378650289 hasAuthorship W4378650289A5038314386 @default.
• W4378650289 hasAuthorship W4378650289A5040984119 @default.
• W4378650289 hasAuthorship W4378650289A5044155836 @default.
• W4378650289 hasAuthorship W4378650289A5046304194 @default.
• W4378650289 hasAuthorship W4378650289A5046639150 @default.
• W4378650289 hasAuthorship W4378650289A5053452787 @default.
• W4378650289 hasAuthorship W4378650289A5069663433 @default.
• W4378650289 hasAuthorship W4378650289A5089214384 @default.
• W4378650289 hasAuthorship W4378650289A5090147778 @default.
• W4378650289 hasAuthorship W4378650289A5092043390 @default.
• W4378650289 hasBestOaLocation W43786502891 @default.
• W4378650289 hasConcept C104317684 @default.
• W4378650289 hasConcept C117643217 @default.
• W4378650289 hasConcept C121608353 @default.
• W4378650289 hasConcept C126322002 @default.
• W4378650289 hasConcept C142724271 @default.
• W4378650289 hasConcept C150194340 @default.

• next